Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) Short Interest Down 12.6% in November

Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) was the target of a large decline in short interest in November. As of November 15th, there was short interest totalling 6,268,579 shares, a decline of 12.6% from the October 31st total of 7,176,264 shares. Approximately 5.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 909,188 shares, the short-interest ratio is presently 6.9 days.

Shares of Synthetic Biologics (SYN) opened at $0.51 on Wednesday. Synthetic Biologics has a 1-year low of $0.41 and a 1-year high of $1.05.

Synthetic Biologics (NYSEAMERICAN:SYN) last posted its quarterly earnings results on Wednesday, November 1st. The company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.10).

A number of equities research analysts have recently weighed in on SYN shares. ValuEngine upgraded shares of Synthetic Biologics from a “strong sell” rating to a “sell” rating in a report on Friday, August 18th. Zacks Investment Research lowered shares of Synthetic Biologics from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Finally, BidaskClub lowered shares of Synthetic Biologics from a “hold” rating to a “sell” rating in a report on Saturday, November 4th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the stock. Synthetic Biologics has a consensus rating of “Hold” and a consensus target price of $3.92.

COPYRIGHT VIOLATION NOTICE: “Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) Short Interest Down 12.6% in November” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply